Labopharm to host conference call Wednesday, May 9, 2007 at 8:30 A.M. (ET)



    - Management to discuss first quarter financial results -

    LAVAL, QC, April 27 /CNW/ - Labopharm Inc. (TSX: DDS; NASDAQ:   DDSS) today
announced that it will host a conference call on Wednesday, May 9, 2007 at
8:30 a.m. (ET) to discuss its first quarter 2007 financial results. Labopharm
will report its first quarter 2007 financial results via news release at
approximately 7:00 a.m. the same day.
    To access the conference call by telephone, dial 416-644-3415 or 
1-800-732-9307. Please connect approximately 15 minutes prior to the beginning
of the call to ensure participation. The conference call will be archived for
replay until Wednesday, May 16, 2007 at midnight. To access the archived
conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation
number 21226864 followed by the number sign.
    A live audio webcast of the conference call will be available at
www.labopharm.com. Please connect at least 15 minutes prior to the conference
call to ensure adequate time for any software download that may be required to
join the webcast. The webcast will be archived at the above web site for 30
days.

    About Labopharm Inc.

    Labopharm Inc. is an international specialty pharmaceutical company
focused on the development of drugs incorporating the Company's proprietary
advanced controlled-release technologies. The Company's lead product, a
once-daily formulation of the analgesic tramadol, has been approved and
launched in Europe and is currently under review for approval by the U.S. Food
and Drug Administration. For more information, please visit www.labopharm.com.

    This press release contains forward-looking statements, which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual events
could differ materially from those projected herein and depend on a number of
factors, including the uncertainties related to the regulatory process and the
commercialization of the Corporation's products thereafter, if they are
approved. Investors should consult the Corporation's ongoing quarterly filings
and annual reports for additional information on risks and uncertainties
relating to these forward-looking statements. The reader is cautioned not to
rely on these forward-looking statements. The Corporation disclaims any
obligation to update these forward-looking statements.





For further information:

For further information: At Labopharm: Mark D'Souza, Chief Financial
Officer, Tel: (450) 686-0207; Sophie Coulombe, Manager, Legal, Corporate
Affairs and Communications, Tel: (450) 680-3221; At The Equicom Group: Jason
Hogan, Media and Investor Relations, Tel: (416) 815-0700,
jhogan@equicomgroup.com; French: Eric Bouchard, Tel: (514) 844-7997,
ebouchard@equicomgroup.com

Organization Profile

LABOPHARM INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890